Recent Updates
Recently added Catalysts

M834

Phase 1

Healthy Volunteers | Monoclonal antibody | Other |Johnson & Johnson|Last Updated: Oct 23, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment243
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02923583Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy SubjectsPHASE1 COMPLETED 243Oct 1, 2016Jul 1, 2017Oct 23, 2017 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
M834BIOLOGICAL -
US-Sourced Orencia®BIOLOGICAL -
EU-Sourced Orencia®BIOLOGICAL -
Unlock Study Design Details